Antiviral Drugs - France

France

France is projected to see a significant increase in revenue within the Antiviral Drugs market.
By 2024, the revenue is estimated to reach US$1.14bn.
This growth is expected to continue with an annual growth rate (CAGR 2024-2028) of -0.66%.
By 2028, the market volume in France is projected to reach US$1.11bn.
When comparing on a global scale, United States is anticipated to generate the highest revenue within the Antiviral Drugs market, with an estimated revenue of US$32,110.00m in 2024.
France is experiencing a surge in demand for antiviral drugs due to the recent increase in viral outbreaks.

Key regions: France, Brazil, South Korea, India, China

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Antiviral Drugs in France has been increasing steadily in recent years.

Customer preferences: Customers in France have been increasingly interested in Antiviral Drugs due to the rise in viral infections such as the flu and COVID-19. Additionally, there has been a growing awareness of the benefits of antiviral drugs in treating viral infections.

Trends in the market: The Antiviral Drugs market in France has been growing due to the rise in viral infections and the increasing demand for antiviral drugs. The market has also been driven by the development of new antiviral drugs and the increasing availability of these drugs in the market.

Local special circumstances: France has a well-developed healthcare system, which has contributed to the growth of the Antiviral Drugs market. The government has also been supportive of the development of new antiviral drugs, which has further boosted the market.

Underlying macroeconomic factors: The growth of the Antiviral Drugs market in France can also be attributed to the country's strong economy and high healthcare spending. Additionally, the aging population in France has contributed to the growth of the market, as older individuals are more susceptible to viral infections and require more medical care.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.